Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Fløisand, Yngvar  [Clear All Filters]
2013
Fernandes AM, Herlofsen SR, Karlsen TA, Küchler AM, Fløisand Y, Brinchmann JE. Similar properties of chondrocytes from osteoarthritis joints and mesenchymal stem cells from healthy donors for tissue engineering of articular cartilage. PLoS One. 2013;8(5):e62994.
2015
Bremer S, Fløisand Y, Brinch L, Gedde-Dahl T, Bergan S. Glutathione transferase gene variants influence busulfan pharmacokinetics and outcome after myeloablative conditioning. Ther Drug Monit. 2015.
2021
Jørgensen SF, Buechner J, Myhre AE, Galteland E, Spetalen S, Kulseth MAnn, Sorte HS, Holla ØL, Lundman E, Alme C, et al. A Nationwide Study of GATA2 Deficiency in Norway-the Majority of Patients Have Undergone Allo-HSCT. J Clin Immunol. 2021.
2023
Fløisand Y, Remberger M, Bigalke I, Josefsen D, Vålerhaugen H, Inderberg EMarit, Olaussen RW, Gjertsen BTore, Goedkoop R, Geiger C, et al. WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy. Leukemia. 2023.
2024
B Grønvold L, Ali MMohamed, Myklebust TÅ, Lenartova A, Remberger M, Abrahamsen IWeum, Tjønnfjord GErland, Myhre AEivind, Fløisand Y, Gedde-Dahl T. Allogeneic stem cell transplant recipients surviving at least 2 years without relapse: outcome and risk factors. EJHaem. 2024;5(1):117-124.
Caulier B, Joaquina S, Gelebart P, Dowling THelén, Kaveh F, Thomas M, Tandaric L, Wernhoff P, Katyayini NUmesh, Wogsland C, et al. CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia. Cell Rep Med. 2024:101572.